FGF21 and metabolic dysfunction-associated steatotic liver disease: Along this line, considering the multiple pathophysiological pathways implicated in the disease, the combination of a GLP-1RA with other agents, such as sodium-glucose cotransporter-2 inhibitor [NCT04639414 and NCT05140694], fibroblast growth factor-21 [NCT05016882], farnesoid X receptor agonist, or Acetyl-CoA carboxylase inhibitor [NCT04971785] for the treatment of MASLD are under investigation.